Long term safety and visibility of a novel liquid ﬁducial marker foruse in image guided radiotherapy of non-small cell lung cancer

Steen Riisgaard de Blanck; Jonas Scherman Rydhög; Klaus Richter Larsen; Paul Frost Clementsen; Mirjana Josipovic; Marianne Camille Aznar; Per Munck af Rosenschöld; Rasmus Irming Jølck; Lena Specht; Thomas Lars Andresen; Gitte Fredberg Persson

doi:10.1016/j.ctro.2018.07.004

Long term safety and visibility of a novel liquid ﬁducial marker foruse in image guided radiotherapy of non-small cell lung cancer

Steen Riisgaard de Blanck^*, Jonas Scherman Rydhög, Klaus Richter Larsen, Paul Frost Clementsen, Mirjana Josipovic, Marianne Camille Aznar, Per Munck af Rosenschöld, Rasmus Irming Jølck, Lena Specht, Thomas Lars Andresen, Gitte Fredberg Persson

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

365 Downloads (Pure)

Abstract

Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiotherapy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomography and fluoroscopy images throughout the treatment course and on computed tomography images during follow-up (0–38 months). Marker volume reduction was seen until 9 months after treatment, after which no further marker breakdown was found. No post-treatment migration or marker related complications were found.

Original language	English
Journal	Clinical and Translational Radiation Oncology
Volume	13
Pages (from-to)	24-28
ISSN	2405-6308
DOIs	https://doi.org/10.1016/j.ctro.2018.07.004
Publication status	Published - 2018

Keywords

Liquid fiducial marker
Image-guided radiotherapy
NSCLC
Endoscopic ultrasound
EBUS

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ctro.2018.07.004

1 s2Final published version, 689 KBLicence: CC BY-NC-ND

OpenUrl availability

Full text

Cite this

de Blanck, S. R., Rydhög, J. S., Larsen, K. R., Clementsen, P. F., Josipovic, M., Aznar, M. C., Rosenschöld, P. M. A., Jølck, R. I., Specht, L., Andresen, T. L., & Persson, G. F. (2018). Long term safety and visibility of a novel liquid ﬁducial marker foruse in image guided radiotherapy of non-small cell lung cancer. Clinical and Translational Radiation Oncology, 13, 24-28. https://doi.org/10.1016/j.ctro.2018.07.004

@article{64da105805054efaaa2ddbcceaa6727f,

title = "Long term safety and visibility of a novel liquid ﬁducial marker foruse in image guided radiotherapy of non-small cell lung cancer",

abstract = "Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiotherapy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomography and fluoroscopy images throughout the treatment course and on computed tomography images during follow-up (0–38 months). Marker volume reduction was seen until 9 months after treatment, after which no further marker breakdown was found. No post-treatment migration or marker related complications were found.",

keywords = "Liquid fiducial marker, Image-guided radiotherapy, NSCLC, Endoscopic ultrasound, EBUS",

author = "{de Blanck}, {Steen Riisgaard} and Rydh{\"o}g, {Jonas Scherman} and Larsen, {Klaus Richter} and Clementsen, {Paul Frost} and Mirjana Josipovic and Aznar, {Marianne Camille} and Rosensch{\"o}ld, {Per Munck af} and J{\o}lck, {Rasmus Irming} and Lena Specht and Andresen, {Thomas Lars} and Persson, {Gitte Fredberg}",

year = "2018",

doi = "10.1016/j.ctro.2018.07.004",

language = "English",

volume = "13",

pages = "24--28",

journal = "Clinical and Translational Radiation Oncology",

issn = "2405-6308",

publisher = "Elsevier",

}

de Blanck, SR, Rydhög, JS, Larsen, KR, Clementsen, PF, Josipovic, M, Aznar, MC, Rosenschöld, PMA, Jølck, RI, Specht, L, Andresen, TL & Persson, GF 2018, 'Long term safety and visibility of a novel liquid ﬁducial marker foruse in image guided radiotherapy of non-small cell lung cancer', Clinical and Translational Radiation Oncology, vol. 13, pp. 24-28. https://doi.org/10.1016/j.ctro.2018.07.004

Long term safety and visibility of a novel liquid ﬁducial marker foruse in image guided radiotherapy of non-small cell lung cancer. / de Blanck, Steen Riisgaard; Rydhög, Jonas Scherman; Larsen, Klaus Richter et al.
In: Clinical and Translational Radiation Oncology, Vol. 13, 2018, p. 24-28.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - Long term safety and visibility of a novel liquid ﬁducial marker foruse in image guided radiotherapy of non-small cell lung cancer

AU - de Blanck, Steen Riisgaard

AU - Rydhög, Jonas Scherman

AU - Larsen, Klaus Richter

AU - Clementsen, Paul Frost

AU - Josipovic, Mirjana

AU - Aznar, Marianne Camille

AU - Rosenschöld, Per Munck af

AU - Jølck, Rasmus Irming

AU - Specht, Lena

AU - Andresen, Thomas Lars

AU - Persson, Gitte Fredberg

PY - 2018

Y1 - 2018

N2 - Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiotherapy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomography and fluoroscopy images throughout the treatment course and on computed tomography images during follow-up (0–38 months). Marker volume reduction was seen until 9 months after treatment, after which no further marker breakdown was found. No post-treatment migration or marker related complications were found.

AB - Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiotherapy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomography and fluoroscopy images throughout the treatment course and on computed tomography images during follow-up (0–38 months). Marker volume reduction was seen until 9 months after treatment, after which no further marker breakdown was found. No post-treatment migration or marker related complications were found.

KW - Liquid fiducial marker

KW - Image-guided radiotherapy

KW - NSCLC

KW - Endoscopic ultrasound

KW - EBUS

U2 - 10.1016/j.ctro.2018.07.004

DO - 10.1016/j.ctro.2018.07.004

M3 - Journal article

C2 - 30258990

SN - 2405-6308

VL - 13

SP - 24

EP - 28

JO - Clinical and Translational Radiation Oncology

JF - Clinical and Translational Radiation Oncology

ER -

Long term safety and visibility of a novel liquid ﬁducial marker foruse in image guided radiotherapy of non-small cell lung cancer

Abstract

Keywords

UN SDGs

Access to Document

OpenUrl availability

Fingerprint

Cite this